HORSHAM, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2024 financial results on Wednesday, August 14, 2024 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, August 14, 2024 to review financial results ...

HORSHAM, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and Chief Executive Officer, and Christopher Lesovitz, Chief Financial Officer, will participate in the 9th Annual Virtual Needham MedTech & Diagnostics 1x1 Conference being held on August 12 – 13, ...

HORSHAM, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and Chief Executive Officer, and Christopher Lesovitz, Chief Financial Officer, will participate in the 9th Annual Virtual Needham MedTech & Diagnostics 1x1 Conference being held on August 12 – 13, 2 ...

HORSHAM, Pa., July 23, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the issuance and sale of 665,136 shares of its common stock at an average purchase price of $3.16 per share for total gros ...

HORSHAM, Penn., July 22, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the approval of its XTRAC Momentum™ 1.0 device by the Ministry of Health, Labor and Welfare of Japan. The Company initially launched the XTRAC Momentum™ in the U.S. in early 2022. The immediate commercial rollout of the device in J ...

Core Insights - STRATA Skin Sciences, Inc. has published a clinical study demonstrating the effectiveness of its TheraClear®X photopneumatic device for treating mild to moderate acne, with results indicating significant improvements in skin conditions after treatment [1][6][13] Company Overview - STRATA Skin Sciences is a medical technology company focused on developing and marketing innovative products for dermatologic conditions, including acne, psoriasis, and vitiligo [14] Clinical Study Findings - The study published in the Journal of Cosmetic and Laser Therapy showed that all patients experienced a visible reduction in acne lesions, achieving at least 50% clearance after three treatments [2][6] - Patients reported improvements in skin texture, including reduced redness, pore size, oiliness, and acne-induced hyperpigmentation [2][6] - Side effects were mild and transient, with patients describing the TheraClear®X treatment as comfortable [2][3] Treatment Mechanism - TheraClearX combines gentle vacuum and pulsed broadband light to treat various forms of acne, effectively targeting Cutibacterium acnes and reducing sebum production [3][11] - The device allows for tailored treatment based on individual acne severity, enhancing the precision of therapy [7][11] Market Potential - Acne affects tens of millions of people in the U.S. annually, highlighting the demand for effective treatment options beyond traditional topical and oral therapies [13]

HORSHAM, Penn., June 12, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the availability of two virtual webinars that discuss the benefits of using its XTRAC® excimer device for the treatment of psoriasis, vitiligo, and eczema and its TheraClear®X photopneumatic device for the treatment of mild to mode ...

Core Insights - STRATA Skin Sciences, Inc. announced positive clinical study results for its TheraClear®X Acne System, demonstrating significant efficacy and safety in treating mild to moderate acne [4][3] - The study showed a notable reduction in acne lesions, with two-thirds of participants achieving at least a one-grade improvement in Investigator's Global Assessment by Day 49 [1][3] - High patient satisfaction was reported, with 80% of participants expressing satisfaction or high satisfaction with the treatment [1][3] Company Overview - STRATA Skin Sciences is a medical technology company focused on developing and marketing innovative products for dermatologic conditions, including acne, psoriasis, and vitiligo [10] - The TheraClear®X device is FDA-cleared and utilizes a combination of gentle vacuum and pulsed broadband light to treat various forms of acne [8] - The company employs a unique Partnership Program that includes a fee per treatment cost structure, providing training and support for practitioners [10][11] Study Details - The clinical study titled "A 7-Week Open-Label Trial Evaluating the Safety and Efficacy of TheraClear®X for Mitigating Mild-to-Moderate Acne" was published in the Journal of Clinical and Aesthetic Dermatology [4] - Conducted by Dr. Glynis Ablon, the study involved six weekly treatment sessions and highlighted the device's customizable settings for tailored treatment [3][5] - The results indicated that TheraClear®X is a viable option for patients who have not responded well to other acne treatments [3]

Dr. Ablon noted, "I am thrilled with the clinical study results for TheraClearX Acne System. The data clearly demonstrates TheraClear®X's efficacy and safety, providing a significant improvement for Acne patients. Noninvasive devices are always needed in the acne armamentarium!" Safe Harbor The study concluded that photopneumatic monotherapy effectively reduces acne lesions across all Fitzpatrick skin types with favorable tolerability and participant satisfaction. Customizable settings allow tailored treatm ...

HORSHAM, Penn., June 04, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its participation in two dermatology conferences in the month of June. On June 1, STRATA has participated in the inaugural Schweiger Symposium at the Jacob Javits Center in New York City. The Symposium brought together dermatology ...